AR101395A1 - Derivados de indolizina y su uso en enfermedades neurodegenerativas - Google Patents
Derivados de indolizina y su uso en enfermedades neurodegenerativasInfo
- Publication number
- AR101395A1 AR101395A1 ARP150102464A ARP150102464A AR101395A1 AR 101395 A1 AR101395 A1 AR 101395A1 AR P150102464 A ARP150102464 A AR P150102464A AR P150102464 A ARP150102464 A AR P150102464A AR 101395 A1 AR101395 A1 AR 101395A1
- Authority
- AR
- Argentina
- Prior art keywords
- sulfur
- nitrogen
- oxygen
- ring
- nrc
- Prior art date
Links
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical class C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 16
- 229910052760 oxygen Inorganic materials 0.000 abstract 12
- 229910052717 sulfur Inorganic materials 0.000 abstract 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 11
- 125000005842 heteroatom Chemical group 0.000 abstract 11
- 229910052757 nitrogen Inorganic materials 0.000 abstract 11
- 239000001301 oxygen Substances 0.000 abstract 11
- 239000011593 sulfur Substances 0.000 abstract 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 6
- 229920006395 saturated elastomer Polymers 0.000 abstract 5
- 125000004429 atom Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000003341 7 membered heterocyclic group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000002837 carbocyclic group Chemical group 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000000172 C5-C10 aryl group Chemical group 0.000 abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004011 3 membered carbocyclic group Chemical group 0.000 abstract 1
- 125000003627 8 membered carbocyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003003 spiro group Chemical group 0.000 abstract 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Un compuesto de fórmula (1), o una sal farmacéuticamente aceptable del mismo, donde: X es -halógeno, -haloalquilo, -O, -SR, -CN, -NO₂, -SO₂R, -SOR, -C(O)R, -CO₂R, -C(O)N(R)₂, -NRC(O)R, -NRC(O)N(R)₂, -NRSO₂R o -N(R)₂; o X es un alifático C₁₋₆, arilo C₅₋₁₀, un anillo carbocíclico saturado o parcialmente insaturado de 3 a 8 miembros, un anillo heterocíclico de 3 a 7 miembros que tiene de 1 a 4 heteroátomos seleccionados, independientemente, entre nitrógeno, oxígeno o azufre, o un anillo heteroarílico monocíclico de 5 a 6 miembros que tiene de 1 a 4 heteroátomos seleccionados, independientemente, entre nitrógeno, oxígeno o azufre; estando cada uno de los cuales opcionalmente sustituido; Y es O, S, SO₂, SO, C(O), CO₂, C(O)N(R), NRC(O), NRC(O)N(R), NRSO₂ o N(R); el anillo A es arilo C₅₋₁₀, un anillo carbocíclico saturado o parcialmente insaturado de 3 a 8 miembros, un anillo heterocíclico de 3 a 7 miembros que tiene de 1 a 4 heteroátomos seleccionados, independientemente, entre nitrógeno, oxígeno o azufre, o un anillo heteroarílico monocíclico de 5 a 6 miembros que tiene de 1 a 4 heteroátomos seleccionados, independientemente, entre nitrógeno, oxígeno o azufre; o un anillo bicíclico, bicíclico condensado, espirobicíclico o policíclico de 6 a 18 miembros que tiene de 0 a 4 heteroátomos seleccionados, independientemente, entre nitrógeno, oxígeno o azufre, estando cada uno de los cuales opcionalmente sustituido; cada R¹ es, independientemente, -R, halógeno, -haloalquilo, -hidroxialquilo, -O, -SR, -CN, -NO₂, -SO₂R, -SOR, -C(O)R, -CO₂R, -C(O)N(R)₂, -NRC(O)R, -NRC(O)N(R)₂, -NRSO₂R o -N(R)₂; o dos grupos R¹, junto con el átomo o los átomos a los que cada uno está unido, pueden formar un anillo condensado o espiro seleccionado entre arilo C₅₋₁₀, un anillo carbocíclico saturado o parcialmente insaturado de 3 a 8 miembros, un anillo heterocíclico de 3 a 7 miembros que tiene de 1 a 4 heteroátomos seleccionados, independientemente, entre nitrógeno, oxígeno o azufre, o un anillo heteroarílico monocíclico de 5 a 6 miembros que tiene de 1 a 4 heteroátomos seleccionados, independientemente, entre nitrógeno, oxígeno o azufre; estando cada uno de los cuales opcionalmente sustituido; Z es -R, halógeno, -haloalquilo, -hidroxialquilo, -O, -SR, -CN, -NO₂, -SO₂R, -SOR, -C(O)R, -CO₂R, -C(O)N(R)₂, -NRC(O)R, -NRC(O)N(R)₂, -NRSO₂R o -N(R)₂-; cada Rᵃ es, independientemente, -R, halógeno, -haloalquilo, -hidroxialquilo, -O, -SR, -CN, -NO₂, -SO₂R, -SOR, -C(O)R, -CO₂R, -C(O)N(R)₂, -NRC(O)R, -NRC(O)N(R)₂, -NRSO₂R o -N(R)₂; cada R es, independientemente, hidrógeno, alifático C₁₋₆, arilo C₃₋₁₀, un anillo carbocíclico saturado o parcialmente insaturado de 3 a 8 miembros, un anillo heterocíclico de 3 a 7 miembros que tiene de 1 a 4 heteroátomos seleccionados, independientemente, entre nitrógeno, oxígeno o azufre, o un anillo heteroarílico monocíclico de 5 a 6 miembros que tiene de 1 a 4 heteroátomos seleccionados, independientemente, entre nitrógeno, oxígeno o azufre; estando cada uno de los cuales opcionalmente sustituido; o dos grupos R del mismo átomo se toman junto con el átomo al que están unidos para formar un arilo C₃₋₁₀, un anillo carbocíclico saturado o parcialmente insaturado de 3 a 8 miembros, un anillo heterocíclico de 3 a 7 miembros que tiene de 1 a 4 heteroátomos seleccionados, independientemente, entre nitrógeno, oxígeno o azufre o un anillo heteroarílico monocíclico de 5 a 6 miembros que tiene de 1 a 4 heteroátomos seleccionados, independientemente, entre nitrógeno, oxígeno o azufre; estando cada uno de los cuales opcionalmente sustituido; m es 1 ó 2; n es 0, 1, 2 ó 3; y p es 0, 1 ó 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462031237P | 2014-07-31 | 2014-07-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101395A1 true AR101395A1 (es) | 2016-12-14 |
Family
ID=53785788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102464A AR101395A1 (es) | 2014-07-31 | 2015-07-31 | Derivados de indolizina y su uso en enfermedades neurodegenerativas |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US9546166B2 (es) |
| EP (1) | EP3174877B1 (es) |
| JP (1) | JP6571756B2 (es) |
| KR (1) | KR20170033339A (es) |
| CN (1) | CN107001356B (es) |
| AR (1) | AR101395A1 (es) |
| AU (1) | AU2015296210B2 (es) |
| BR (1) | BR112017001221A2 (es) |
| CA (1) | CA2954681A1 (es) |
| ES (1) | ES2927587T3 (es) |
| IL (1) | IL250267B (es) |
| MX (1) | MX2017001103A (es) |
| RU (1) | RU2017105133A (es) |
| SG (1) | SG11201700140TA (es) |
| WO (1) | WO2016019228A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010030111A1 (de) | 2009-08-11 | 2011-02-17 | Evonik Degussa Gmbh | Wässrige Silansysteme für den Blankkorrosionsschutz und Korrosionsschutz von Metallen |
| CN107709299B (zh) | 2015-04-24 | 2021-07-16 | 盐野义制药株式会社 | 6元杂环衍生物及含有其的药物组合物 |
| CN116332886A (zh) | 2016-07-18 | 2023-06-27 | 广州瑞安博医药科技有限公司 | 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法 |
| RU2753524C2 (ru) | 2016-10-17 | 2021-08-17 | Сионоги Энд Ко., Лтд. | Бициклические азотсодержащие гетероциклические производные и включающие их фармацевтические композиции |
| FI3609868T3 (fi) | 2017-03-13 | 2023-11-22 | Raqualia Pharma Inc | Tetrahydrokinoliinijohdannaisia P2X7-reseptorin antagonisteina |
| CA3088968C (en) * | 2018-01-18 | 2023-10-17 | Daiichi Sankyo Company, Limited | Dihydroindolizinone derivative |
| EA202191545A1 (ru) | 2018-12-06 | 2021-10-28 | Артроси Терапьютикс, Инк. | Кристаллические формы соединения для лечения или профилактики подагры или гиперурикемии |
| EP3890722A4 (en) | 2018-12-06 | 2022-08-24 | Arthrosi Therapeutics, Inc. | METHODS OF TREATMENT OR PREVENTION OF GOUT OR HYPERURICEMIA |
| AU2020256166A1 (en) | 2019-04-02 | 2021-10-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
| JP7553030B2 (ja) * | 2019-07-08 | 2024-09-18 | 国立大学法人東京工業大学 | ジヒドロインドリジノン誘導体を用いたインスリン産生細胞の作製法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19731153A1 (de) * | 1997-07-21 | 1999-01-28 | Basf Ag | 2-(Pyrazolyl- und Triazolyl-3'-oxymethylen)-phenyl-isoxazolone und -triazolone, Verfahren zu ihrer Herstellung und ihre Verwendung |
| AU2001278006A1 (en) | 2000-07-27 | 2002-02-13 | Smithkline Beecham Corporation | Agonists of follicle stimulating hormone activity |
| CN101848909A (zh) * | 2006-02-14 | 2010-09-29 | 沃泰克斯药物股份有限公司 | 可用作蛋白激酶抑制剂的吡咯并[3,2-c]吡啶 |
| WO2008124153A1 (en) * | 2007-04-10 | 2008-10-16 | H. Lundbeck A/S | Heteroaryl amide analogues as p2x7 antagonists |
| DK2835131T3 (en) * | 2010-12-14 | 2017-12-04 | Electrophoretics Ltd | Casein kinase 1 delta inhibitors (CK1 delta) |
-
2015
- 2015-07-31 CA CA2954681A patent/CA2954681A1/en active Pending
- 2015-07-31 MX MX2017001103A patent/MX2017001103A/es unknown
- 2015-07-31 AR ARP150102464A patent/AR101395A1/es unknown
- 2015-07-31 EP EP15747950.2A patent/EP3174877B1/en active Active
- 2015-07-31 CN CN201580050359.2A patent/CN107001356B/zh not_active Expired - Fee Related
- 2015-07-31 KR KR1020177003586A patent/KR20170033339A/ko not_active Withdrawn
- 2015-07-31 JP JP2017505203A patent/JP6571756B2/ja not_active Expired - Fee Related
- 2015-07-31 US US14/814,659 patent/US9546166B2/en not_active Expired - Fee Related
- 2015-07-31 WO PCT/US2015/043090 patent/WO2016019228A1/en not_active Ceased
- 2015-07-31 RU RU2017105133A patent/RU2017105133A/ru unknown
- 2015-07-31 BR BR112017001221A patent/BR112017001221A2/pt not_active Application Discontinuation
- 2015-07-31 SG SG11201700140TA patent/SG11201700140TA/en unknown
- 2015-07-31 AU AU2015296210A patent/AU2015296210B2/en not_active Ceased
- 2015-07-31 ES ES15747950T patent/ES2927587T3/es active Active
-
2016
- 2016-12-06 US US15/370,645 patent/US9931324B2/en active Active
-
2017
- 2017-01-25 IL IL250267A patent/IL250267B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ES2927587T3 (es) | 2022-11-08 |
| EP3174877A1 (en) | 2017-06-07 |
| US20160031879A1 (en) | 2016-02-04 |
| WO2016019228A1 (en) | 2016-02-04 |
| US9546166B2 (en) | 2017-01-17 |
| EP3174877B1 (en) | 2022-06-29 |
| IL250267B (en) | 2021-05-31 |
| JP2017522347A (ja) | 2017-08-10 |
| CA2954681A1 (en) | 2016-02-04 |
| MX2017001103A (es) | 2017-04-27 |
| BR112017001221A2 (pt) | 2017-11-28 |
| AU2015296210B2 (en) | 2019-08-15 |
| SG11201700140TA (en) | 2017-02-27 |
| CN107001356B (zh) | 2019-09-03 |
| IL250267A0 (en) | 2017-03-30 |
| US9931324B2 (en) | 2018-04-03 |
| CN107001356A (zh) | 2017-08-01 |
| JP6571756B2 (ja) | 2019-09-04 |
| KR20170033339A (ko) | 2017-03-24 |
| AU2015296210A1 (en) | 2017-02-02 |
| RU2017105133A (ru) | 2018-08-28 |
| US20170079965A1 (en) | 2017-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR101395A1 (es) | Derivados de indolizina y su uso en enfermedades neurodegenerativas | |
| AR103138A1 (es) | Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos | |
| AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
| EA201692010A1 (ru) | Фармацевтическое соединение | |
| CY1125004T1 (el) | Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
| MX2016011632A (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| AR100058A1 (es) | DERIVADOS DE PIRIMIDIN-PIRAZINAS FUSIONADAS MODULADORES DE RORg | |
| AR099785A1 (es) | Compuestos heteroarilos y su uso como medicamentos | |
| UY35485A (es) | Compuestos heterocíclicos y usos de los mismos | |
| AR096241A1 (es) | Inhibidores de acc y usos de los mismos | |
| AR094964A1 (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd) | |
| AR110088A1 (es) | Inhibidores de magl | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100724A1 (es) | Derivados de quinolina y su uso en enfermedades neurodegenerativas | |
| CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| AR101290A1 (es) | Inhibidores de aldosterona sintasa | |
| CU20160166A7 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| MX2016015247A (es) | Derivados de benceno-sulfonamida y su uso como moduladores del receptor c huerfano relacionado a acido retinoico (rorc). | |
| AR111271A1 (es) | Inhibidores dobles de magl y faah | |
| JOP20190049A1 (ar) | مثبطات دوبامين-b-هيدروكسيلاز |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |